Key facts
- Veinway’s last known valuation is $18.0M (Jan 2025).
- It has raised $10.3M; the latest was Later Stage VC ($7.0M) in Jan 2025.
- Notable investors include MassChallenge, MedTech Innovator, Innovation Authority, Consensus Business Group, ARC Innovation Center — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Veinway
- ·The full record, as it builds
Funding rounds
No funding rounds for Veinway are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Veinway
Operator of a pre-clinical medical device company intended to change the paradigm of treating chronic venous disease. The company's platform provides physicians with a dedicated, purpose-built tool to create a pathway through a clogged vein, such that physicians can easily restore blood flow through the vein to the heart, enabling users to safely cross a variety of complicated blockages that were previously un-crossable, as well as shorten the time to cross.
- Sector
- Healthcare
- HQ
- Or Yehuda, Israel
- Founded
- 2020
- Employees
- 4
- Website
- veinway.com/
- Ownership
- Privately Held (backing)
Veinway doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Veinway shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Veinway in its N-PORT filings yet. We sweep new filings monthly.